Wang Yunlong, Deng Xuan, Qiu Qinggui, Wan Mengchao
Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Department of Outpatient, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Front Oncol. 2024 Jul 12;14:1431023. doi: 10.3389/fonc.2024.1431023. eCollection 2024.
To investigate the risk factors associated with cardiotoxicity in patients with non-small cell lung cancer (NSCLC) treated with osimertinib.
A total of 268 patients with NSCLC treated with osimertinib in our hospital from June 2019 to December 2023 were selected to observe the occurrence of cardiotoxicity and were divided into cardiotoxicity group and non-cardiotoxicity group. The differences in age, gender, body mass index (BMI), smoking, alcohol consumption, tumor stage, hypertension, diabetes, hyperlipidemia, chemotherapy, radiotherapy, antiangiogenic drugs, and osimertinib treatment time were recorded and analyzed. Logistic regression was used to analyze the risk factors for cardiotoxicity in patients with non-small cell lung cancer caused by osimertinib treatment.
Among the 268 patients with NSCLC treated with osimertinib, 58 patients developed cardiotoxicity, and the incidence of cardiotoxicity was 21.64%. There were statistically significant differences between the cardiotoxicity group and the non-cardiotoxicity group in terms of smoking history, hyperlipidemia history, combined chemotherapy, and combined radiotherapy (P < 0.05). Further analysis showed that patients with a smoking history were at increased risk of cardiotoxicity compared with non-smoking patients (OR = 2.569, 95% CI = 1.398-6.523). Patients with hyperlipidemia were at increased risk of cardiotoxicity compared with those without hyperlipidemia (OR = 3.412, 95% CI = 2.539-7.628). Patients with chemotherapy were at increased risk of cardiotoxicity compared with those without combination chemotherapy (OR = 2.018, 95% CI = 1.426-4.517). Patients undergoing radiotherapy to the left chest were at increased risk of cardiotoxicity compared with those without combined radiotherapy (OR = 1.629, 95% CI = 1.273-4.206).
The incidence of cardiotoxicity in patients with NSCLC is high due to osimertinib treatment. A history of smoking, hyperlipidemia, combination chemotherapy, and radiotherapy to the left chest are independent risk factors for cardiotoxicity in patients with NSCLC treated with osimertinib.
探讨奥希替尼治疗非小细胞肺癌（NSCLC）患者发生心脏毒性的相关危险因素。
选取2019年6月至2023年12月在我院接受奥希替尼治疗的268例NSCLC患者，观察心脏毒性的发生情况，并分为心脏毒性组和非心脏毒性组。记录并分析两组患者的年龄、性别、体重指数（BMI）、吸烟、饮酒、肿瘤分期、高血压、糖尿病、高脂血症、化疗、放疗、抗血管生成药物及奥希替尼治疗时间的差异。采用Logistic回归分析奥希替尼治疗所致非小细胞肺癌患者发生心脏毒性的危险因素。
在268例接受奥希替尼治疗的NSCLC患者中，58例发生心脏毒性，心脏毒性发生率为21.64%。心脏毒性组与非心脏毒性组在吸烟史、高脂血症病史、联合化疗及联合放疗方面差异有统计学意义（P<0.05）。进一步分析显示，有吸烟史的患者发生心脏毒性的风险高于不吸烟患者（OR=2.569，95%CI=1.398-6.523）。有高脂血症的患者发生心脏毒性的风险高于无高脂血症者（OR=3.412，95%CI=2.539-7.628）。接受化疗的患者发生心脏毒性的风险高于未接受联合化疗者（OR=2.018，95%CI=1.426-4.517）。接受左胸放疗的患者发生心脏毒性的风险高于未接受联合放疗者（OR=1.629，95%CI=1.273-4.206）。
奥希替尼治疗NSCLC患者心脏毒性发生率较高。吸烟史、高脂血症、联合化疗及左胸放疗是奥希替尼治疗NSCLC患者发生心脏毒性的独立危险因素。
